TD Cowen Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $67
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
TD Cowen analyst Ritu Baral initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $67.
TD Cowen analyst Ritu Baral initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $67.